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of a planning scan. There is no tool describing doses outside 
this region or relating all calculated doses to radiosensitive 
organs to long-term adverse effects e.g. second cancer 
induction and/or cardiac events.  
We have developed a new software program called aRRESt 
(Radiotherapy Risk Evaluation System) which provides an 
interactive 3D visualisation of second cancer and cardiac risks 
in out-of-field organs. It can be used to compare classes of 
treatment plan and aid decision-making. The ultimate aim is 
to provide individualised risk profiles on a per-patient basis. 
Materials and Methods: A cross-platform graphical user 
interface (GUI) was developed using the Python programming 
language, with 3D visualisation and interaction provided by 
the Visualisation Tool Kit (VTK) module. The GUI provides an 
indication of lifetime attributable risk (LAR) of second cancer 
induction using the BEIR VII risk model [1], and the total risk 
of major coronary events caused by excess heart dose from 
Darby et al [2]. 
The program works by extracting the dose cube and outlined 
regions of interest (ROI) from DICOM files exported from a 
commercial treatment planning system. Mean organ doses are 
calculated from this data, and are used to estimate the 
LAR/cardiac risk.  
Results: The program has been tested on treatment plans 
extracted from the Philips Pinnacle treatment planning 
system. These plans were based on a full body CT scan of the 
anthropomorphic Rando phantom, with approximate organ 
positions outlined by an expert practitioner. Meaningful 
differences between plan types were clearly visible (see Fig. 
1). Initial feedback from clinicians was positive. 
 
 
 
Figure 1: Top: LAR risk profiles for SIB and APBI left breast 
treatment plans delivered at an age of 60 years. Left breast, 
contralateral lung and bladder second cancer risks are shown, 
alongside risk of a major coronary event. Bottom: 3D 
interactive visualisation of ROIs outlined on a CT scan of the 
Rando phantom, extracted from the Pinnacle treatment 
planning system.  
 
Conclusions: The aRRESt program provides a quick and 
convenient method of visualising the risks of second cancer 
induction between different radiotherapy treatment 
deliveries. The underlying uncertainties in the risk models 
used are large, but as more data is accumulated and a better 
understanding of radiobiology is obtained, more sophisticated 
risk models can easily be incorporated into the software. 
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Purpose/Objective: The incidence of lower third 
oesophageal tumours are increasing in most Western 
populations (1) and it is becoming increasingly clear that 
chemo-radiotherapy (CRT) is now a viable alternative to 
surgical resection in the treatment of both oesophageal and 
gastroesophageal junction (GEJ) cancer (2). With the role of 
radiotherapy dose escalation being identified as a research 
priority in improving outcomes (3), it is important to quantify 
the increased toxicity that this may pose to sites such as the 
lower oesophagus that have vital adjacent organs that up to 
now may not have been taken into consideration. This study 
therefore aims to investigate the feasibility of lower 
oesophageal dose escalation with a focus on stomach tissue 
toxicity. 
Materials and Methods: 10 patients from the SCOPE 1 
database classified as having with tumours in the lower 
region were selected at random. The original 3D conformal 
treatment plan (503D) was available for review and was 
compared to two RapidArc plans created retrospectively to 
represent the treatment arms of the forthcoming SCOPE 2 
trial: RA50 and RA60 (PTV 50Gy with a simultaneously 
integrated boost of 60Gy to PTV2). The stomach was 
contoured as both whole organ and stomach wall and dose 
constraints set according to QUANTEC (4). 
Plans were compared using dose metrics and radiobiological 
modelling of TCP was performed using the model by Geh et al 
(5). Normal tissue complication probability (NTCP) was 
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estimated for the stomach and stomach wall with endpoints 
of ulceration and gastric bleeding respectively (6) & (7).  
Results: The stomach wall model showed larger values of 
NTCP than the whole stomach. There was a mean increase of 
5.93% (-0.42, 18.71%) in NTCP from the 50Gy3D to the 60GyRA 
plans and a mean increase of 8.15% (-0.42, 19.79%) in NTCP 
from the 50GyRA to the 60GyRA plans. When the NTCP 
modelling is restricted to that outside PTV2, there was a 
mean decrease of 0.92% (-4.70, 1.00%) in NTCP from the 
50Gy3D to the 60GyRA plans, and a mean increase of 2.25% (-
0.42, 6.91%) in NTCP from the 50GyRA to the 60GyRA plans. 
There was a strong correlation between the NTCP value and 
the Stomach Wall/PTV1 overlap volume for all treatment 
plans (Pearson’s R=0.80, 0.77 and 0.77 for the 60GyRA, 50GyRA 
and 50Gy3D plans respectively). There was also a strong 
correlation between the NTCP value and the Stomach 
Wall/PTV2 overlap volume for the 60GyRA plan (R= 0.82). 
Conclusions: Radiobiological modelling suggests that 
increasing the prescribed dose to 60Gy may be associated 
with a significantly increased risk of toxicity to the stomach. 
The results of this study also suggest that the maximum 
prescribed dose safely achievable for each patient in the 
future may be dependent on the volume of the stomach 
within the treatment volume. It is recommended that 
stomach toxicity be closely monitored prospectively when 
treating patients with lower oesophageal tumours in the 
forthcoming SCOPE 2 trial. 
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Purpose/Objective: The Italian Association of Medical Physics 
(AIFM) instituted in 2012 a working group dedicated to the 
Stereotactic ablative body radiotherapy (SABR). The aim of 
this work is to identify possible criticisms in approaching 
multicentric clinical trial for lung SABR, comparing, from a 
radiobiologic and dosimetric point of view, the plans 
obtained with different treatment planning systems, 
techniques and planners. 
Materials and Methods: Five CT series from a database of 
patients treated with RT on lung were sent to the 
participants. Dose prescription was 54 Gy in 3 fractions of 18 
Gy each to planning target volume (PTV). Each participant 
was asked to prescribe dose in conformity to its experience 
(i.e. 100%, 80%, mean dose) to stress the individuality of 
every center. For all plans were calculated: the PTV gEUD 
(generalized equivalent uniform dose), the MLD (mean lung 
dose) equivalent to 2 Gy for ipsilateral lung minus CTV and 
OAR (organ at risk) maximum dose. The dosimetric data and 
the parameters related to each center were analyzed 
including : expertise, equipment, size of leaves, TPS, 
radiation technique, and energy of radiation. Furthermore, a 
performance index was defined for each dosimetric 
parameter to compare plans with diferences in terms of the 
PTV gEUD. For example the performance index regarding 
MLDeq2Gy is defined a PI =  
(MLDeq2Gy/gEUD)Reference/(MLDeq2Gy/ gEUD)center. and 
the Reference value belongs to a center with mean 
performances. 
Results: Twenty-six centers with 3D-Conformal RT, IMRT, 
VMAT (Linac 88%), CyberKnife (4%) and Tomotherapy (8%) 
